Expression of γH2AX in various gastric pathologies and its association with Helicobacter pylori infection

CHUAN XIE*, LI-YAO XU*, ZHEN YANG, XI-MEI CAO, WEI LI and NONG-HUA LU

Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi 330006, P.R. China

Received May 6, 2013; Accepted November 12, 2013

DOI: 10.3892/ol.2013.1693

Abstract. Phosphorylation of H2AX at Ser 139 (γH2AX) is a biomarker of DNA double-strand breaks (DSBs). The present study aimed to explore the association between γH2AX levels and gastric pathology and Helicobacter pylori (H. pylori) infection. Gastric biopsies were obtained from 302 H. pylori-negative and -positive patients, including those with chronic gastritis (CG), intestinal metaplasia (IM), dysplasia (Dys) and gastric cancer (GC). Proteins were extracted from five gastric epithelial cell lines and from 10 specimens of matched GC and adjacent normal tissues. The expression of γH2AX, a biomarker for the detection of DNA DSBs, in gastric tissues was detected by immunohistochemistry and western blotting. The expression of γH2AX progressively increased in tissues according to pathological stage from CG to Dys, but was slightly decreased in GC. H. pylori infection was associated with increased γH2AX expression, IM and Dys. Overexpression of γH2AX in GC was found to correlate with tumor location, gross appearance, differentiation, depth of invasion, TNM stage and lymph node metastasis. The results indicated that DSBs appear to be an early molecular event in gastric carcinogenesis, which may be associated with H. pylori infection. Moreover, immunohistochemical staining of γH2AX was found to correlate with a number of clinicopathological characteristics. The expression of γH2AX may serve as a valuable biomarker for the diagnosis and progression of GC.

Introduction

Gastric cancer (GC) is the fourth most common malignancy and the second leading cause of cancer mortality worldwide (1). Helicobacter pylori (H. pylori) is a gram-negative bacteria that infects 50% of the global population. However, in certain regions and countries of the world, >80% of the population is infected with the bacteria. H. pylori has been defined by the International Agency for Research of Cancer as a class I carcinogen and is important for the progression from chronic superficial gastritis to chronic atrophic gastritis, intestinal metaplasia (IM), dysplasia (Dys) and finally GC (2).

DNA double-strand breaks (DSBs) are the most serious type of DNA damage and are frequently caused by ionizing radiation (IR), ultraviolet light and specific chemical agents. Recently, H. pylori has also been shown to induce DSBs in gastric epithelial cells in vitro (3,4). Inappropriate repair of DSBs can result in genomic instability, which has been shown to be a key factor in carcinogenesis (5). Phosphorylation of H2AX at Ser 139 (γH2AX) is abundant, fast, correlates well with DSBs and renders γH2AX a sensitive marker for the detection of DSBs (6). The expression of γH2AX has been shown to correlate with numerous types of malignant tumor and also with prognosis in early operable non-small cell lung cancer, vulvar squamous cell carcinoma and breast cancer (7-9).

There have been a number of studies on γH2AX expression in GC tissues. Sentani et al (10) showed that nuclear positive staining for GC was significantly higher than that in normal gastric tissues. However, no previous studies have investigated γH2AX expression in various gastric lesions or its correlation with H. pylori infection. Therefore, the aim of the present study was to measure the expression of γH2AX and determine its correlation with the various stages of gastric carcinogenesis, in the presence or absence of H. pylori infection.

Patients and methods

Patients and sample collection. Gastric tissue samples were collected from patients who had undergone an upper gastro-duodenoscopy or gastrectomy at the First Affiliated Hospital of Nanchang University (Nanchang, China) between January 2007 and September 2008. A total of 302 patients ranging in age between 18 and 70 years were enrolled in the current study. The study included 56 cases of chronic gastritis (CG), 53 of IM, 47 of Dys and 146 of GC. None of the patients had been treated with proton pump inhibitors or antibiotics against H. pylori, and no GC patients had been treated with prior radio- or chemotherapy. The clinical characteristics of these patients are summarized in Table I. No significant differences were identified in the age or gender distribution among these groups. Clinicopathological characteristics were also obtained from the pathological reports.

Correspondence to: Professor Nong-Hua Lu, Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, 17 Yongwai Road, Nanchang, Jiangxi 330006, P.R. China E-mail: lunonghua@ncu.edu.cn

*Contributed equally

Key words: Helicobacter pylori, DNA double-strand breaks, γH2AX, gastric carcinogenesis
In total, 10 GC tissue samples and adjacent normal tissues were collected from gastrectomy specimens at the First Affiliated Hospital of Nanchang University.

The present study was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University. All patients provided written informed consent prior to enrollment in the study.

**Histological examination.** All biopsies or surgical specimens from the patients with gastric disease were obtained from the gastric antrum or lesion locations. The tissues used for histological analysis were fixed in 10% formaldehyde in Ca²⁺ and Mg²⁺-free phosphate-buffered saline (PBS) overnight at 4°C, prior to paraffin embedding. Paraffin sections, 4 µm thick, were sectioned with a microtome and stored at room temperature. Pathological diagnosis and classification were performed according to the criteria of the World Health Organization (11) and the updated Sydney system (12).

**Detection of H. pylori infection.** Rapid urease test and modified Giemsa staining were used for the detection of *H. pylori* infection. The modified Giemsa staining was performed by two veteran pathologists. Consistency in the positive or negative results of the two tests was required.

**Immunohistochemistry.** Slices were deparaffinized in dimethylbenzene, rehydrated through 100, 95 and 85% ethanol and incubated with fresh 3% H₂O₂ for 10 min to quench endogenous peroxidase activity. Microwave heating was used to expose antigens for detection. The primary antibody used for immunohistochemistry was rabbit monoclonal anti-human γH2AX (ab81299; 1:400; Abcam, Cambridge, UK). Slices were incubated at 4°C overnight and then washed with PBS three times. The secondary antibody (PV-6000; Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China) was incubated at 37°C for 30 min prior to reaction with 3,3-diaminobenzidine (Zhongshan Golden Bridge Biotechnology Co., Ltd.). Subsequently, slices were counterstained with hematoxylin and mounted with coverslips. Negative controls consisted of PBS without primary antibody (13).

**Review and scoring.** The stained slices were reviewed and scored by two experienced pathologists. The concordance rates were generally high and results with any grading discrepancies were re-reviewed and discussed to determine a final score. Epithelial cells stained yellow or brown in the nuclei were defined as positive. Five fields for each slice were randomly selected, reviewed and scored (magnification, x200). In each field, 100 immunoreactive cells were assessed and quantified as the percentage of total cells and then averaged from the five fields to calculate the percentage of immunostaining, i.e. 0, ≤5.0%; 1, 5.1-25.0%; 2, 25.1-50.0%; 3, 50.1-75.0%; and 4, >75.0%. Moreover, the staining intensity was also semi-quantitatively assessed as follows: 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining. The integrals of the ‘area x intensity’ were calculated based on the following overall scores of the expression levels of the proteins in the sections: negative (-), 0-2; weak positive (+), 3-5; moderate positive (++), 6-8; and strong positive (+++), 9-12 (Table I) (13).

**Cell lines and culture.** Five gastric mucosal cell lines were used in the present study, including GES-1 (immortalized gastric epithelial mucosa cell line, established by the Beijing Institute for Cancer Research, Beijing, China) and human gastric cancer SGC7901, MKN28, MKN45 and AGS cell lines (a gift from the Xijing Hospital of Digestive Disease, Xi’an, China). Cell lines were cultured at 37°C in an atmosphere of 5% CO₂ in DMEM with 10% fetal bovine serum, 100 units penicillin and 100 µg/ml streptomycin (Gibco-BRL, Carlsbad, CA, USA) (14).

**Western blotting.** Tissues and cells were lysed in a buffer containing 0.5% Lubrol-PX, 50 mM KCl, 2 mM CaCl₂, 20% glycerol, 5 mM Tris-HCl (pH 7.4), 0.1% protease and 1% phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Following the addition of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer, proteins were run on an SDS-PAGE gel and transferred to nitrocellulose membranes (Whatman GmbH, Dassel, Germany). The membranes were immunoblotted with antibodies against γH2AX (ab81299; 1:1,000; Abcam) and actin (1:1,000; Zhongshan Golden Bridge Biotechnology Co., Ltd.). The reactions were subjected to incubation with an enhanced chemiluminescence detection system (Pierce Biotechnology, Inc., Rockford, IL, USA) and then exposed to X-ray film for visualizing the positive bands.

**Statistical analysis.** SPSS 17.0 (SPSS Inc., Chicago, IL, USA) was used to perform the statistical analysis. Data are expressed as the mean ± standard deviation or percentage. The χ² test was used to evaluate differences in categorical variables. The Kruskal-Wallis one-way analysis of variance and Mann-Whitney U tests were used to determine differences in numerical variables between various groups. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Differential expression of γH2AX in various gastric lesions and its association with H. pylori infection.** Immunohistochemical analysis showed that γH2AX was primarily found in the nuclei of epithelial cells. Semi-quantitative results of the expression of γH2AX are shown in Table I. The results showed that the expression ratio of γH2AX was 48.2% in the CG group, 73.5% in the IM group, 95.7% in the Dys group and 89.7% in the GC group. Consistent with the observations of Correa et al (2), the expression levels of γH2AX in the current study were significantly increased as pathological stages progressed from CG to Dys (P<0.001). However, expression levels were decreased in GC (P=0.011) (Fig. 1 and Table I). The expression of γH2AX was also measured by western blotting in GC and adjacent normal tissues. The results showed high γH2AX expression in GC tissues compared with adjacent normal tissues (P<0.001) (Fig. 2), which is consistent with the immunohistochemical results.

Moreover, in patients with IM and Dys, the expression of γH2AX was significantly higher in the presence of *H. pylori* infection (96.5 and 100%, respectively) compared with those without the infection (45.8 and 90.4%, respectively) (P=0.001 and P=0.008) (Table II). However, no significant differences were detected in the CG or GC groups.
The association of γH2AX expression with clinicopathological parameters was analyzed in 146 GC patients (Table III). The gastric body and cardia cancers showed a higher γH2AX expression (97.2%) than gastric antrum cancers (82.4%) (P<0.001). In addition, the expression of γH2AX in Borrmann III and IV type GC (90.5%) was significantly higher than Borrmann I and II type GC (88.9%) (P=0.002). γH2AX expression in poorly- and undifferentiated GC (93.8%) was significantly higher compared with that in well- and moderately differentiated GC (89.7%) (P<0.001).

Table I. Expression of γH2AX in patients with various histological observations.

| Group | n   | Mean age (SD), years | Gender, M/F | Overall score of γH2AX expression |
|-------|-----|----------------------|-------------|---------------------------------|
| 1 CG  | 56  | 53.6 (10.7)          | 30/26       | -  29  27  0  0  48.2           |
| 2 IM  | 53  | 54.3 (9.6)           | 29/24       | +  14  26  12  1  73.5 <0.001 |
| 3 Dys | 47  | 55.1 (10.3)          | 26/21       | ++  2  9  27  9  95.7 <0.001 |
| 4 GC  | 146 | 56.8 (14.1)          | 96/50       | +++  15  57  50  24  89.7 <0.001 |

*Percentage of immunostaining. **vs. CG group; ***vs. IM group; ****vs. Dys group. γH2AX, phosphorylated H2AX at Ser 139; M, male; F, female; CG, chronic gastritis; IM, intestinal metaplasia; Dys, dysplasia; GC, gastric cancer.
Table II. Expression of γH2AX in patients with various histological observations, in relation to H. pylori infection.

| Group | H. pylori | n  | Mean age (SD), years | Gender, M/F | Overall score of γH2AX expression |
|-------|-----------|----|----------------------|-------------|----------------------------------|
|       |           |    |                      |             | - , n  | + , n | ++, n | +++ , n | %a | P-value |
| CG    | +         | 26 | 54.1 (11.7)          | 14/12       | 7      | 19    | 0     | 0       | 73.1 | 0.362   |
|       | -         | 30 | 53.2 (9.1)           | 16/14       | 22     | 8     | 0     | 0       | 26.7 |         |
| IM    | +         | 29 | 54.8 (8.8)           | 14/15       | 1      | 19    | 8     | 1       | 96.5 | 0.001   |
|       | -         | 24 | 53.7 (10.3)          | 15/9        | 13     | 7     | 4     | 0       | 45.8 |         |
| Dys   | +         | 26 | 54.3 (12.2)          | 13/13       | 0      | 2     | 17    | 7       | 100.0 | 0.008   |
|       | -         | 21 | 56.1 (9.5)           | 13/8        | 2      | 7     | 10    | 2       | 90.4  |         |
| GC    | +         | 61 | 58.3 (16.3)          | 39/22       | 6      | 25    | 20    | 10      | 90.2  | 0.865   |
|       | -         | 85 | 50.8 (13.9)          | 57/28       | 9      | 32    | 30    | 14      | 89.4  |         |

| Group | H. pylori | n  | Mean age (SD), years | Gender, M/F | Overall score of γH2AX expression |
|-------|-----------|----|----------------------|-------------|----------------------------------|
|       |           |    |                      |             | - , n  | + , n | ++, n | +++ , n | %a | P-value |
| CG    | +         | 26 | 54.1 (11.7)          | 14/12       | 7      | 19    | 0     | 0       | 73.1 | 0.362   |
|       | -         | 30 | 53.2 (9.1)           | 16/14       | 22     | 8     | 0     | 0       | 26.7 |         |
| IM    | +         | 29 | 54.8 (8.8)           | 14/15       | 1      | 19    | 8     | 1       | 96.5 | 0.001   |
|       | -         | 24 | 53.7 (10.3)          | 15/9        | 13     | 7     | 4     | 0       | 45.8 |         |
| Dys   | +         | 26 | 54.3 (12.2)          | 13/13       | 0      | 2     | 17    | 7       | 100.0 | 0.008   |
|       | -         | 21 | 56.1 (9.5)           | 13/8        | 2      | 7     | 10    | 2       | 90.4  |         |
| GC    | +         | 61 | 58.3 (16.3)          | 39/22       | 6      | 25    | 20    | 10      | 90.2  | 0.865   |
|       | -         | 85 | 50.8 (13.9)          | 57/28       | 9      | 32    | 30    | 14      | 89.4  |         |

| Group | H. pylori | n  | Mean age (SD), years | Gender, M/F | Overall score of γH2AX expression |
|-------|-----------|----|----------------------|-------------|----------------------------------|
|       |           |    |                      |             | - , n  | + , n | ++, n | +++ , n | %a | P-value |
| CG    | +         | 26 | 54.1 (11.7)          | 14/12       | 7      | 19    | 0     | 0       | 73.1 | 0.362   |
|       | -         | 30 | 53.2 (9.1)           | 16/14       | 22     | 8     | 0     | 0       | 26.7 |         |
| IM    | +         | 29 | 54.8 (8.8)           | 14/15       | 1      | 19    | 8     | 1       | 96.5 | 0.001   |
|       | -         | 24 | 53.7 (10.3)          | 15/9        | 13     | 7     | 4     | 0       | 45.8 |         |
| Dys   | +         | 26 | 54.3 (12.2)          | 13/13       | 0      | 2     | 17    | 7       | 100.0 | 0.008   |
|       | -         | 21 | 56.1 (9.5)           | 13/8        | 2      | 7     | 10    | 2       | 90.4  |         |
| GC    | +         | 61 | 58.3 (16.3)          | 39/22       | 6      | 25    | 20    | 10      | 90.2  | 0.865   |
|       | -         | 85 | 50.8 (13.9)          | 57/28       | 9      | 32    | 30    | 14      | 89.4  |         |

*Percentage of immunostaining. γH2AX, phosphorylated H2AX at Ser 139; H. pylori: Helicobacter pylori; M, male; F, female; CG, chronic gastritis; IM, intestinal metaplasia; Dys, dysplasia; GC, gastric cancer.

Table III. Clinicopathological association of γH2AX expression in patients with GC.

| Characteristics | n  | - , n | + , n | ++, n | +++ , n | PR, % | P-value |
|-----------------|----|-------|-------|-------|---------|-------|---------|
| Gender          |    |       |       |       |         |       |         |
| Male            | 96 | 8     | 39    | 35    | 14      | 91.7  | 0.923   |
| Female          | 50 | 7     | 18    | 15    | 10      | 86.0  |         |
| Age, years      |    |       |       |       |         |       |         |
| ≥55             | 86 | 7     | 36    | 28    | 15      | 91.8  | 0.780   |
| <55             | 60 | 8     | 21    | 22    | 9       | 86.7  |         |
| Location        |    |       |       |       |         |       |         |
| Antrum          | 74 | 13    | 31    | 25    | 5       | 82.4  | <0.001  |
| Body and cardia | 72 | 2     | 26    | 25    | 19      | 97.2  |         |
| Gross type (Borrmann) |    |       |       |       |         |       |         |
| I and II        | 72 | 8     | 37    | 21    | 6       | 88.9  | 0.002   |
| III and IV      | 74 | 7     | 20    | 29    | 18      | 90.5  |         |
| Differentiation |    |       |       |       |         |       |         |
| Well and moderately | 81 | 11    | 40    | 21    | 9       | 74.1  |         |
| Poorly and undifferentiated | 65 | 4     | 17    | 29    | 15      | 93.8  | <0.001  |
| Invasive depth  |    |       |       |       |         |       |         |
| Above submucosa | 27 | 4     | 18    | 3     | 2       | 85.1  |         |
| Muscularis propria | 8  | 2     | 0     | 3     | 3       | 75.0  | 0.080a  |
| Below subserosa | 111| 9     | 39    | 44    | 19      | 91.9  | 0.002b; 0.373b |
| TNM             |    |       |       |       |         |       |         |
| I and II        | 59 | 8     | 35    | 12    | 3       | 86.4  | <0.001  |
| III and IV      | 87 | 7     | 22    | 38    | 20      | 91.9  |         |
| Lymph node metastasis |     |       |       |       |         |       |         |
| With            | 113| 10    | 37    | 45    | 21      | 91.2  | 0.002   |
| Without         | 33 | 5     | 20    | 5     | 3       | 84.8  |         |

*vs. above submucosa; b vs. muscularis propria. γH2AX, phosphorylated H2AX at Ser 139; GC, gastric cancer; PR, positive rate.

differentiated GC (74.1%) (P<0.001). In cancer tissues located in the submucosa, the γH2AX expression (85.1%) was significantly lower than that in cancer tissues that had reached the subserosal level (91.9%) (P=0.002). Furthermore, γH2AX was expressed more frequently in TNM III and IV stage patients (91.9%) than in TNM I and II stage patients (86.4%) (P<0.001), and there was
higher γH2AX expression in the patients with lymph node metastasis (91.2%) than in the patients without (84.8%) (P=0.002).

Differential expression of γH2AX in various gastric epithelial cell lines. Expression of γH2AX was higher in GC cell lines (i.e., SGC-7901, MKN-28 and AGS, with the exception of MKN-45) compared with the non-cancerous cell lineGES-1 (Fig. 3).

Discussion

DSBs are important threats to genome integrity causing chromosomal aberrations, which are remarkable characteristics of malignant tumors (15). While the response to DNA damage acts as an anticancer barrier in early human tumorigenesis, γH2AX has been reported to be highly overexpressed in precancerous lesions of the urinary bladder, breast, lung and colon cancer (16). In the current study, the expression of γH2AX was shown to progressively increase in accordance with the pathological progression from CG to Dys. γH2AX expression in GC was also higher than that in CG, but was slightly decreased in Dys. The reason for lower γH2AX expression in GC compared with Dys remains unclear; however, restoration of genomic instability during tumor progression may explain this observation (17,18). The western blotting results of the cancer and adjacent normal tissues were confirmed by cell line experiments. All results showed that the response to DNA damage was activated in gastric precancerous lesions.

Recently, Toller et al have shown that H. pylori triggers DSBs in gastric epithelial cells in cell culture, primarily mediated by H. pylori blood group antigen-binding adhesion (3). In addition, Jang et al have shown that H. pylori-induced DSBs may be inhibited by lycopene (4). The two investigations were based on AGS coculture with H. pylori in cell culture, a model system which is different from the clinical situation. The results of the current study were based on human samples and showed that high expression of γH2AX in IM and Dys patients appeared to correlate with H. pylori infection, which implied that H. pylori not only induces DSBs in cell culture, but may also be involved in an early molecular event in gastric tumorigenesis. However, whether the DNA damage response pathways are impaired requires further study.

The observations of the current study have shown that the overexpression of γH2AX in GC correlates with a number of clinicopathological characteristics, including tumor location, tumor gross type, differentiation, tumor invasion depth, TNM stage and lymph node metastasis. All these correlations implied that, as the degree of malignancy increased, the genomic instability was also significantly increased. These results confirm previous observations by Sentani et al (10), in which the expression of the γH2AX protein in GC was significantly higher in non-neoplastic gastric mucosa and its high expression was also found to correlate with stage II-IV cases. Exposure to IR was an important factor in the study.

In conclusion, DSBs appear to be an early molecular event in gastric carcinogenesis, which is associated with H. pylori infection and a number of clinical characteristics. Although the exact mechanism by which DSBs are induced by H. pylori infection remains unclear, the expression of γH2AX may serve as a valuable biomarker for the diagnosis and progression of GC.

Acknowledgements

The current study was supported in part by grants from the National Natural Science Foundation of China (no. 81270479) and the Graduate Innovative Foundation of Jiangxi Province, China (no. YC2013-B004).

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52: 6735-6740, 1992.
3. Toller IM, Neelsen KJ, Steger M, Hartung ML, Hottiger MO, Stucki M, et al: Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc Natl Acad Sci USA 108: 14944-14949, 2011.
4. Jang SH, Lim JW, Jang J, Lim SB, Morito T and Kim H: Lycopene inhibits Helicobacter pylori-induced ATM/ATR-dependent DNA damage response in gastric epithelial AGS cells. Free Radic Biol Med 52: 607-613, 2012.
5. Smith J, Tho LM, Xu N and Gillespie DA: The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signalling and cancer. Adv Cancer Res 108: 73-112, 2012.
6. Sharma A, Singh K and Almasan A: Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol 920: 613-626, 2012.
7. Mathioudakis D, Fokas PG, Kefala M, Hountis P, Trypisgianis G, Panayiotides IG, et al: γ-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. Onco Targets Ther 5: 309-314, 2012.
8. Brustmann H, Hinterholzer S and Brunner A: immunohistochemical expression of survivin and γ-H2AX in vulvar intrapithelial neoplasia and low-stage squamous cell carcinoma. Int J Gynecol Pathol 30: 583-590, 2011.
9. Nagelkerke A, van Kuijk SJ, Sweep FC, Nagtegaal ID, Hoogerbrugge N, Martens JW, et al: Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer. Radiother Oncol 101: 39-45, 2011.
10. Sentani K, Oue N, Sakamoto N, Nishisaka T, Fukuhara T, Matsuura H and Yasui W: Positive immunohistochemical staining of gammaH2AX is associated with tumor progression in gastric cancers from radiation-exposed patients. Oncol Rep 20: 1131-1136, 2008.
11. Hamilton SR and Aaltonen LA (eds): Pathology and genetics of tumours of the digestive system. In: World Health Organization Classification of Tumours. IARC Press, Lyon, 2000.
12. Dixon MF, Genta RM, Yardley JH and Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20: 1161-1181, 1996.
13. Yang Z, Shu X, Chen L, Chen J, Xie Y and Lu NH: Expression of p53-MDM2 feedback loop related proteins in different gastric pathologies in relation to Helicobacter pylori infection: implications in gastric carcinogenesis. Clin Res Hepatol Gastroenterol 36: 235-243, 2012.
14. Yang Z, Yuan XG, Chen J, Luo SW, Luo ZJ and Lu NH: Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: a novel mechanism of PTEN inactivation. Clin Res Hepatol Gastroenterol 37: 72-79, 2013.
15. van Gent DC, Hoejmakers JH and Kanaar R: Chromosomal instability and the DNA double-stranded break connection. Nat Rev Genet 2: 196-206, 2001.
16. Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, et al: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870, 2005.
17. Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S and Bishop DK: RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 67: 9658-9665, 2007.
18. Martin RW, Connell PP and Bishop DK: The Yin and Yang of treating BRCA-deficient tumors. Cell 132: 919-920, 2008.